NovaBay Pharmaceuticals, Inc. (NBY) Hammered 3.67% Today: What The Technicals Suggest?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is a big mover this session as the company shares are trading 3.67% or 0.017 points lower from last closing price of $0.46, reaching $0.4431 at last check. So what’s going on with NBY shares anyway? The price has dropped in 4 of the last 5 days and is down -78.2% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -78,388 shares, and in total 524412 shares valued at $232367 were seen changing hands compared with 602800 shares valued at $277288 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the NBY stock is near its bottom.

NovaBay Pharmaceuticals, Inc. (NBY) shares have notched a 3-month decline of about -78.2%, but has still tumbled -40.47% year to date. By comparison, the stock sank -68.69% over the past 12 months, while it slipped -51.64% over the 1 month. The company’s market cap is around $12.29M, with its short interest ratio standing at 0.09%.

In the current trading session for NBY, the stock witnessed two major price actions, it rose to a high of $0.4667 and was down as much as $0.4301 at one point. The high recorded is very low when compared to their 52-week high which is $0.23. The 52-week high is now at -89.13 distance from current price. Their recent low of $4.04 represents a 91.75% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for NBY is $1.5, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of NovaBay Pharmaceuticals, Inc. earned $-0.54 per share in the trailing 12 months and has a P/E ratio of -0.82. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 30.46 and lower compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. NBY also has P/S multiple of 1.18. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.34x.

NBY‘s last price was down -61.97% as compared to the average trading price of 50 days recorded at $1.17 while enlarging the period to 200 trading days, the average closing price was $1.03. At present, there are 26.72 million in the total number of common shares owned by the public and among those 13.23 million shares have been available to trade. The percentage of shares being held by the company management was 46.7% while institutions stake was 2.6%. The company has generated negative returns on equity over the last 12 months (-275%). It managed to keep its gross profit margin at 84.9% over the past 12 months.

When assessing the full upside of the NBY stock, there is another set of technicals that should be looked into and considered. Its -28.41% decline from moving average of $0.62 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 4.94 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

In the last five years, the EPS of the company has been roughly 48.3%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 29.2 over the last five years. The company recently recorded a drop of -35.7%, but this figure is rather unattractive.